What is the recommended approach to diagnosing early disseminated neurologic Lyme disease?

Diagnosing Early Disseminated Neurologic Lyme Disease

For patients with suspected early disseminated neurologic Lyme disease, diagnose based on compatible neurologic symptoms plus epidemiologic tick exposure, confirmed by serum antibody testing using two-tiered serology (ELISA followed by Western blot); CSF testing with simultaneous CSF:serum antibody index determination is recommended only for CNS involvement, not for peripheral nervous system manifestations like isolated cranial neuropathy. 1

Clinical Presentations That Warrant Testing

Test for Lyme disease when patients present with these acute neurologic syndromes AND plausible tick exposure 1:

• Meningitis (lymphocytic pattern, typically <10% polymorphonuclear cells)
• Painful radiculoneuritis (often the hallmark presentation)
• Cranial neuropathies - particularly CN VII (facial nerve palsy, can be bilateral), CN VIII, and less commonly CN III, V, VI
• Mononeuropathy multiplex including confluent patterns
• Spinal cord inflammation especially when associated with painful radiculitis at corresponding segments
• Brain inflammation (rare in early disseminated disease)

Key Clinical Clues

In children with Lyme meningitis versus viral meningitis, look for 2:

• Longer symptom duration (median 17 days vs. 2 days for viral)
• Less likely to be febrile
• Presence of erythema migrans, cranial nerve palsy, or papilledema (found in ~90% of Lyme meningitis, none with viral)

Diagnostic Algorithm

Step 1: Serum Antibody Testing (Primary Diagnostic Tool)

Use two-tiered serology as the cornerstone 1:

1. Initial ELISA screening
2. If positive or equivocal → Western blot for both IgM and IgG

Critical timing considerations:

• The vast majority of patients with early neurologic Lyme disease are seropositive 2
• For the small proportion who are seronegative initially, obtain convalescent serum ~2 weeks later 2
• IgM alone beyond 6 weeks typically represents false positive 3
• Only IgG confirms diagnosis in established disease 3

Step 2: CSF Testing (Selective Use)

When to perform CSF analysis 1:

• CNS involvement (meningitis, encephalitis, myelitis)
• NOT routinely needed for isolated peripheral nervous system manifestations (cranial neuropathy, radiculoneuropathy)

If CSF testing is done 1:

• Obtain simultaneous CSF and serum samples
• Calculate CSF:serum antibody index using validated laboratory methodology
• Do NOT order CSF serology without the antibody index
• Intrathecal antibody synthesis achieves >99% sensitivity after 6-8 weeks 3

Important caveat: Isolated antibody index elevation without CSF pleocytosis suggests alternative etiologies 3. A true CNS infection should show either pleocytosis OR pathogen-specific intrathecal antibody production 4.

Step 3: Avoid These Testing Pitfalls

Do NOT use 1:

• PCR or culture of CSF or serum as primary diagnostic tools (low yield, not validated)
• CSF serology alone without antibody index calculation
• Testing in patients without compatible clinical syndromes and epidemiologic exposure

What NOT to Test For

Strongly recommend AGAINST routine Lyme testing in 1:

• Typical ALS, relapsing-remitting MS, Parkinson's disease
• Dementia or cognitive decline
• New-onset seizures
• Psychiatric illness (adults or children)
• Developmental or behavioral disorders (children)
• Nonspecific brain MRI white matter abnormalities without other clinical/epidemiologic support

Common Diagnostic Errors to Avoid

1. Over-reliance on serology alone: 10-30% of populations in endemic areas are seropositive 5. Clinical context is mandatory.

2. Misinterpreting persistent IgG: Antibodies may remain for years after successful treatment 6, 3. Positive serology does not equal active disease.

3. Ordering CSF testing for isolated facial palsy: Cranial neuropathy without other CNS signs does not require lumbar puncture 1, 2.

4. Testing too early: In symptoms <6 weeks with negative initial serology, repeat testing after 3 weeks 3.

5. Accepting isolated IgM as diagnostic: Beyond 6 weeks of symptoms, isolated IgM is typically false positive 3.

Epidemiologic Context is Essential

Always confirm plausible tick exposure in endemic areas 1. The diagnosis requires both compatible clinical presentation AND appropriate exposure history. Without epidemiologic support, testing should not be performed even with neurologic symptoms 1.

The 2020 IDSA/AAN/ACR guidelines 1 represent the most authoritative and recent evidence, superseding the 2006 guidelines 2 while maintaining core diagnostic principles with refined specificity about when and how to test.